Ferring Pharmaceuticals has acquired two Phase III orthobiologic product candidates from BioSurface Engineering Technologies, Inc. (BioSET). The drugs, AMPLEX and PREFIX, will be investigated in foot/ankle and lumbar spine fusion surgical procedures, respectively. Both drugs are based on a biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair. “With the acquisition of the BioSET portfolio, Ferring intends to build on its growing success in orthopaedics,” said ...